Cargando…

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Ovarian cancer is the deadliest gynecological malignancy of the reproductive organs in the United States. Cyclin-dependent kinase 1 (CDK1) is an important cell cycle regulatory protein that specifically controls the G2/M phase transition of the cell cycle. RO-3306 is a selective, ATP-competitive, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yu, Fan, Yali, Zhao, Ziyi, Zhang, Xin, Tucker, Katherine, Staley, Allison, Suo, Hongyan, Sun, Wenchuan, Shen, Xiaochang, Deng, Boer, Pierce, Stuart R., West, Lindsay, Yin, Yajie, Emanuele, Michael J., Zhou, Chunxiao, Bae-Jump, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418904/ https://www.ncbi.nlm.nih.gov/pubmed/37569750 http://dx.doi.org/10.3390/ijms241512375

Ejemplares similares

Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
por: O'donnell, Jillian, et al.
Publicado: (2023)

Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer
por: Fan, Yali, et al.
Publicado: (2022)

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer
por: Jackson, Amanda L., et al.
Publicado: (2017)

Asparagus officinalis Exhibits Anti-Tumorigenic and Anti-Metastatic Effects in Ovarian Cancer
por: Xu, Guangxu, et al.
Publicado: (2021)

Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer
por: Xu, Guangxu, et al.
Publicado: (2023)

Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma
por: Wu, Chuan Xing, et al.
Publicado: (2018)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Oleic Acid Exhibits Anti-Proliferative and Anti-Invasive Activities via the PTEN/AKT/mTOR Pathway in Endometrial Cancer
por: Deng, Boer, et al.
Publicado: (2023)

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer
por: Stine, Jessica E., et al.
Publicado: (2015)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro
por: Zhang, Yingao, et al.
Publicado: (2020)

ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells
por: Luo, N, et al.
Publicado: (2016)

Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer
por: Guo, Hui, et al.
Publicado: (2016)

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer
por: Paraghamian, Sarah E., et al.
Publicado: (2023)

Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer
por: Sun, Li, et al.
Publicado: (2017)

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
por: Pierce, Stuart R., et al.
Publicado: (2021)

TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells
por: Kang, Kyung Taek, et al.
Publicado: (2018)

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer
por: Suri, Anuj, et al.
Publicado: (2016)

A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells
por: Di Palma, Tina, et al.
Publicado: (2014)

RoBERTa-Assisted Outcome Prediction in Ovarian Cancer Cytoreductive Surgery Using Operative Notes
por: Laios, Alexandros, et al.
Publicado: (2023)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo
por: Zhang, Lu, et al.
Publicado: (2016)

MSC stimulate ovarian tumor growth during intercellular communication but reduce tumorigenicity after fusion with ovarian cancer cells
por: Melzer, Catharina, et al.
Publicado: (2018)

Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells
por: Zhou, Qi, et al.
Publicado: (2015)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*
por: Qiu, Haifeng, et al.
Publicado: (2015)

Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells
por: Pagotto, Anna, et al.
Publicado: (2017)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway
por: Yuan, Lingqin, et al.
Publicado: (2015)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
por: Liu, Chen, et al.
Publicado: (2022)

HADHA promotes ovarian cancer outgrowth via up-regulating CDK1
por: Liu, Yinglan, et al.
Publicado: (2023)

EphA2 promotes tumorigenicity of cervical cancer by up‐regulating CDK6
por: Huang, Changhao, et al.
Publicado: (2021)

Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer
por: Yang, Wookyeom, et al.
Publicado: (2016)

Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells
por: Wang, Jiandong, et al.
Publicado: (2014)

Switch of the ovarian cancer cell to a calcifying phenotype in the calcification of ovarian cancer
por: Wen, Jirui, et al.
Publicado: (2018)

Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
por: Eoh, Kyung Jin, et al.
Publicado: (2018)

PHOSPHATE exporter XPR1/SLC53A1 is required for the tumorigenicity of epithelial ovarian cancer
por: Akasu‐Nagayoshi, Yoko, et al.
Publicado: (2022)

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
por: Iyengar, Mangala, et al.
Publicado: (2018)

ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma
por: Yanagida, Satoshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qqt494479f29ij9000uk3q49b4